GLP-1 receptor agonists reduced heart failure events by 59% and decreased CRP and NT-proBNP levels but did not affect cardiovascular death in obesity-related HFpEF.
Do GLP-1 receptor agonists reduce heart failure events and improve biomarkers in patients with obesity-related HFpEF?
GLP-1 receptor agonists significantly reduce heart failure-related events and improve inflammatory and hemodynamic biomarkers in patients with obesity-related HFpEF.
Absolute Event Rate: 0% vs 0%
Abstract Background The prevalence of heart failure with preserved ejection fraction (HFpEF) is rising, particularly among individuals with obesity, who experience significant symptom burden and functional impairment. Currently, no treatments have been approved specifically targeting obesity-related HFpEF. This study evaluates the effects of glucagon-like peptide-1 (GLP-1) receptor agonists on clinical outcomes in this population. Methods We systematically searched PubMed, Embase, and Cochrane Central databases following PRISMA guidelines, identifying randomized controlled trials (RCTs) comparing GLP-1 receptor agonists with placebo or standard treatment in patients with HFpEF and obesity. We assessed the adjudicated heart failure events, death from cardiovascular causes, change from baseline in N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels, and percent change from baseline in C-reactive protein (CRP) levels. The risk ratio (RR) with 95% confidence intervals (CI) was used for dichotomous outcomes, while standardized mean differences (SMD) and mean differences (MD) with 95% CI were applied to continuous variables. Heterogeneity was assessed using the I² statistic. All statistical analyses were carried out using R software (version 4.2.2). Results Three RCTs were included, comprising 1,876 patients, of whom 937 received a GLP-1 receptor agonist. Follow-up ranged from 52 to 104 weeks. Treatment with GLP-1 receptor agonists significantly reduced heart failure-related events by 59% compared to placebo (RR 0.41; 95% CI 0.21, 0.81; p=0.01). In addition, there was a significant decrease in C-reactive protein levels (SMD -0.45; 95% CI -0.57, -0.29; p0.001) and in NT-proBNP levels (MD -0.15; 95% CI -0.22, -0.09; p0.001). However, no significant changes were observed between the groups when analyzing death from cardiovascular causes rate (RR 0.79; 95% CI 0.22, 2.86; p=0.72). Conclusion GLP-1 receptor agonists significantly reduced heart failure-related events, systemic inflammation, and NT-proBNP levels, but did not impact cardiovascular mortality. These findings suggest potential benefits of GLP-1 receptor agonists in obesity-related HFpEF beyond traditional heart failure markers, supporting their emerging role as a targeted therapy for this high-risk population.CV Death + Heart failure events Change in PCR levels + NT-proBNP levels
Rosa et al. (Sat,) reported a other. GLP-1 receptor agonists reduced heart failure events by 59% and decreased CRP and NT-proBNP levels but did not affect cardiovascular death in obesity-related HFpEF.